As European markets continue to reach record levels, buoyed by a rally in technology stocks and expectations for lower U.S. borrowing costs, investors are exploring diverse opportunities within the region. Penny stocks, often overlooked due to their vintage-sounding name, still represent a relevant investment area today. These smaller or newer companies can offer significant growth potential when they possess solid financial foundations and strong fundamentals.
Name
Share Price
Market Cap
Financial Health Rating
Ariston Holding (BIT:ARIS)
€4.05
€1.4B
★★★★★☆
Lucisano Media Group (BIT:LMG)
€1.15
€17.08M
★★★★★☆
Maps (BIT:MAPS)
€3.26
€43.3M
★★★★★★
DigiTouch (BIT:DGT)
€2.03
€27.66M
★★★★★★
Angler Gaming (NGM:ANGL)
SEK3.60
SEK269.95M
★★★★★★
Angler Gaming (DB:0QM)
€0.37
€221.96M
★★★★★★
Hove (CPSE:HOVE)
DKK4.49
DKK113.52M
★★★★★★
Siili Solutions Oyj (HLSE:SIILI)
€4.89
€39.65M
★★★★★★
Hifab Group (OM:HIFA B)
SEK3.40
SEK206.85M
★★★★★☆
Deceuninck (ENXTBR:DECB)
€2.10
€290.26M
★★★★★★
Click here to see the full list of 271 stocks from our European Penny Stocks screener.
Let’s explore several standout options from the results in the screener.
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: ELES Semiconductor Equipment S.p.A. designs, manufactures, and sells test equipment and solutions for the semiconductor industry both in Italy and internationally, with a market cap of €40.54 million.
Operations: The company’s revenue is primarily derived from its Semiconductor Equipment and Services segment, totaling €34.55 million.
Market Cap: €40.54M
ELES Semiconductor Equipment, with a market cap of €40.54 million, operates in the semiconductor industry but remains unprofitable despite generating €34.55 million in revenue from its equipment and services segment. The company’s short-term assets exceed both its short and long-term liabilities, indicating solid liquidity management. However, its interest coverage ratio is low at 1.6x EBIT, suggesting potential challenges in meeting debt obligations without improved profitability. Recently, Mare Engineering Group acquired a 29.99% stake in ELES for €11.9 million through a hostile takeover bid, reflecting strategic interest despite ELES’s current financial struggles and declining half-year revenue results.
BIT:ELES Financial Position Analysis as at Oct 2025
Simply Wall St Financial Health Rating: ★★★★☆☆
Story Continues
Overview: Cellectis S.A. is a clinical-stage biotechnology company focused on developing gene-editing products, including allogeneic chimeric antigen receptor T-cells for immuno-oncology and gene therapy candidates for other therapeutic areas, with a market cap of €235.42 million.
Operations: The company’s revenue is primarily derived from its Therapeutics segment, amounting to $63.44 million.
Market Cap: €235.42M
Cellectis S.A., with a market cap of €235.42 million, is navigating significant legal challenges due to a recent lawsuit from Factor Bioscience Inc. alleging patent infringement related to mRNA TALENs technology. Despite this, Cellectis has reported increased revenue of US$30.22 million for the first half of 2025, though it remains unprofitable with a net loss of US$41.86 million over the same period. The company maintains strong liquidity as its short-term assets surpass liabilities and holds more cash than debt, but faces volatility in share price and limited cash runway if current spending continues without additional funding or revenue growth.
ENXTPA:ALCLS Debt to Equity History and Analysis as at Oct 2025
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Viscom SE develops, manufactures, and sells inspection systems for industrial production applications across Europe, the Americas, and Asia with a market cap of €43.54 million.
Operations: The company’s revenue is segmented geographically with €28.85 million from Asia, €23.31 million from Germany, €12.39 million from the Americas, and €45.87 million from Europe (excluding Germany).
Market Cap: €43.54M
Viscom SE, with a market cap of €43.54 million, is navigating financial challenges while maintaining a stable asset position. The company reported a net loss of €0.64 million for the first half of 2025, an improvement from the previous year’s larger losses. Despite being unprofitable and having increased its debt to equity ratio over five years, Viscom’s short-term assets comfortably cover both short and long-term liabilities. Analysts expect earnings growth but note that the stock trades significantly below its estimated fair value. Management has confirmed revenue targets between €80 to €90 million for 2025 with modest EBIT margins anticipated.
XTRA:V6C Financial Position Analysis as at Oct 2025
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include BIT:ELES ENXTPA:ALCLS and XTRA:V6C.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com